Comparison between paediatric Kawa-COVID-19 cohort and adult Kawa-COVID cohort
| Clinical and biological results | Adult Kawa-COVID (N=9) | Paediatric Kawa-COVID-19 cohort (N=16) | P value |
| Median age (IQR) | 25 (19–33) | 10 (4.7–12.5) | |
| Male gender | 5 (55%) | 8 (50%) | 1.0 |
| Comorbidities; n (%) | 4 | 6 (37%) | 1.0 |
| Overweight | 4 | 4 | 0.63 |
| Clinical features: n (%) | |||
| Fever | 9 (100%) | 16 (100%) | 1.0 |
| Skin rash | 1 (11%) | 13 (81%) | 0.035 |
| Hands and feet erythema/oedema | 2 (22%) | 11 (68%) | 0.14 |
| Conjunctivitis | 4 (44%) | 15 (94%) | 0.062 |
| Dry cracked lips | 1 (9%) | 14 (87%) | 0.024 |
| Cervical lymphadenopathy | 3 (33%) | 6 (37%) | 0.84 |
| Gastrointestinal signs | 8 (88%) | 13 (81%) | 1.0 |
| Neurological signs | 6 (66%) | 9 (56%) | 0.69 |
| Respiratory symptoms | 8 (88%) | 2 (12%) | 0.0003 |
| KDSS | 4 (44%) | 7 (14%) | 0.67 |
| Complete Kawasaki disease: n (%) | 0 | 10 (71%) | <0.0001 |
| Biological results: median (IQR) | |||
| CRP (mg/L) | 363 (278–439) | 207 (162–236) | 0.0004 |
| Platelets (g/L) | 240 (128–243) | 188 (164–244) | 0.64 |
| Lymphocytes (g/L) | 0.6 (0.33–0.87) | 1.15 (0.8–1.7) | 0.023 |
| Natremia (mmol/L) | 132 (129–134) | 130 (127–134) | 0.91 |
| Creatinine (µmol/L) | 140 (83–439) | 59 (44–124) | * |
| Albumin (g/L) | 24 (20–25) | 21 (19–23) | 0.29 |
| SGOT (UI/L) | 120 (75–166) | 48 (33–86) | 0.012 |
| SGPT (UI/L) | 103 (69–139) | 35 (33–86) | 0.042 |
| Ferritinaemia (g/L) | 2124 (833–6205) | 1067 (272–1709) | 0.049 |
| Troponin (ng/L) | 1164 (765–2666) | 58 (36–165) | 0.006 |
| BNP (pg/ml) | 24 540 (2585–35 000) | 4319 (2747–6493) | 0.17 |
| Echocardiography abnormalities: n (%) | 9 (100%) | 11 (69%) | |
| Myocarditis | 9 (100%) | 7 (44%) | 0.008 |
| Coronary dilations | 1 (11%) | 3 (19%) | 0.63 |
| Pericarditis | 1 (11%) | 4 (25%) | 0.32 |
| Treatment: n (%) | |||
| Intravenous Ig | 6 (66%) | 15 (93%) | 0.12 |
| Single infusion | 6 (66%) | 9 (56%) | 0.69 |
| Second infusion | 0 | 6 (37%) | 0.057 |
| Steroids | 3 (33%) | 3 (18%) | 0.63 |
| No anti-inflammatory treatment | 3 (33%) | 1 (6%) | 0.12 |
*No statistical analysis was possible due to different standards between children and adults.
BNP, brain natriuretic peptide; CRP, C reactive protein; Ig, immunoglobulin; KDSS, Kawasaki disease shock syndrome; SGOT, Serum glutamic oxaloacetic transaminase; SGPT, serum glutamic pyruvic transaminase.